Endometriosis and Diabetes Risk: What the New Evidence Shows

New findings are sharpening the debate around endometriosis and diabetes risk. A large observational study reports that women diagnosed with endometriosis were 46% more likely to develop type 2 diabetes than women without the condition. The result does not establish that endometriosis causes diabetes, but it adds metabolic health to a condition usually framed around pelvic pain, bleeding and fertility.

At the same time, diabetes researchers are arguing for prevention across the life course, while work in postmenopausal women continues to examine how diet and body composition relate to insulin resistance. Together, these signals suggest a wider clinical question: should metabolic risk be considered earlier in women with chronic reproductive conditions, rather than waiting for blood glucose to cross a diagnostic threshold?

What the endometriosis and diabetes risk finding means

Endometriosis is an inflammatory, estrogen-responsive condition in which tissue resembling the uterine lining grows outside the uterus. Its effects vary widely. Some women have severe pain or heavy bleeding; others first receive a diagnosis during fertility investigations. Diagnosis can also take years, creating a long period in which symptoms and related health changes may go insufficiently assessed.

The reported 46% increase is a relative risk estimate. It does not mean that nearly half of women with endometriosis will develop diabetes, nor does it reveal an individual woman’s absolute risk. That depends on age, family history, ethnicity, body composition, activity, sleep, medications, previous gestational diabetes and baseline glucose regulation.

Because the study is observational, several explanations remain possible. Endometriosis itself may contribute to metabolic risk, shared biological factors may predispose women to both conditions, or differences in treatment and healthcare use may influence the association. Residual confounding is also possible, even when researchers adjust for known risk factors. The finding is best treated as a reason for closer investigation, not proof of a direct causal pathway.

Inflammation, hormones and insulin sensitivity may overlap

Endometriosis involves altered immune activity and persistent inflammation. Chronic inflammatory signalling can interfere with insulin action in other conditions, making it biologically plausible that endometriosis and impaired glucose regulation could overlap. Plausibility, however, is not confirmation. Researchers still need to establish whether inflammatory activity, disease severity or specific endometriosis subtypes predict metabolic outcomes.

Hormonal exposures may matter too. Endometriosis symptoms are often managed with combined hormonal contraception, progestogens or medications that suppress ovarian hormone production. These treatments differ substantially, and their metabolic effects can vary according to formulation, dose, duration and the person’s underlying risk profile. The new association should not be interpreted as evidence that standard hormonal treatment causes diabetes.

Daily symptoms may influence risk indirectly. Pelvic pain, heavy bleeding and fatigue can reduce activity or disrupt sleep. Poor sleep can temporarily worsen insulin sensitivity and appetite regulation, while reduced movement can affect glucose handling over time. If symptoms make eating patterns less regular or limit training, those secondary effects could also contribute. These pathways are credible, but the proportion of risk attributable to each one remains unknown.

Glucose changes can begin before diabetes

Type 2 diabetes generally develops gradually. Insulin resistance may rise for years while the pancreas compensates by producing more insulin, keeping glucose within or near the reference range. Prediabetes is a later warning stage, but it is not necessarily an inevitable step toward diabetes.

An international expert panel is now calling for prevention to focus more explicitly on remission of prediabetes and to take a life-course view, beginning before pregnancy and extending through older adulthood. For women with endometriosis, that approach could mean considering reproductive history and chronic symptoms alongside established metabolic factors rather than treating gynecological and metabolic health as separate domains.

Common clinical markers include fasting glucose and HbA1c, which estimates average glucose exposure over roughly two to three months. Depending on the clinical context, a clinician may also use an oral glucose tolerance test, blood pressure and lipid measurements. No single marker captures the whole picture, and routine insulin testing is not universally recommended for screening.

The relevant evidence does not yet establish a special screening schedule for every woman with endometriosis. Still, the diagnosis may reasonably become part of a broader risk conversation, particularly when it coexists with a family history of diabetes, polycystic ovary syndrome, previous gestational diabetes, higher central adiposity or persistently abnormal glucose markers.

Risk continues to change after the reproductive years

Menopause adds another layer. Falling estrogen, ageing, changes in muscle mass and shifts in fat distribution can reduce insulin sensitivity even when body weight changes little. Exploratory research in postmenopausal women is examining relationships among dietary factors, adiposity and several insulin-resistance markers, reinforcing that metabolic health cannot be inferred from weight alone.

This matters for endometriosis because the condition’s implications do not necessarily end when menstrual cycles stop. Lesions often become less active after menopause, but a history of chronic inflammation, disrupted activity or treatment exposure may remain relevant to long-term health. Whether endometriosis independently predicts diabetes after menopause, and whether risk differs by treatment or surgical history, needs more targeted study.

Measures of waist circumference and body composition can add context, but they are not diagnoses. Muscle is a major site of glucose disposal, so preserving muscle through resistance training and adequate nutrition is metabolically relevant across adulthood. Equally, normal body mass index does not rule out insulin resistance, particularly when family history or prior pregnancy-related glucose problems are present.

Reading cycle symptoms alongside metabolic signals

The practical message is not that pelvic pain predicts a glucose spike or that every symptom fluctuation reflects insulin resistance. Menstrual timing, pain, bleeding, energy, sleep and appetite can all vary for multiple reasons. A single difficult cycle is rarely informative in isolation. Repeated patterns are more useful, especially when paired with clinically measured markers rather than consumer-device estimates alone.

Consistent records can help distinguish a cyclical change from a persistent one. For example, fatigue limited to the late luteal phase carries different information from fatigue that progressively worsens across the month, while reduced training recovery may be more interpretable when sleep disruption and pain are recorded at the same time. Such observations cannot diagnose diabetes or determine its cause, but they can make a clinical history more precise.

Cycle symptoms, sleep quality, energy and training recovery only become readable when they are logged consistently over weeks. This is the kind of pattern Tulsy is built to surface.

Sources: Medical Xpress, Nature.

This content is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and should not replace advice from a qualified healthcare professional.